Contributions of diet and lifestyle to sex differences in ischaemic heart disease burden in Central Europe: an analysis of the Global Burden of Disease Study 2023 Authors: Raffaele Bugiardini, Tania Rahaman, Lina Badimon, Edina Cenko, Sonia S Anand, Olivia Manfrini, Bela Merkely, Davor Milicic, Nick Townsend, Viola Vaccarino, Martha Gulati, Chris P Gale Published: 2026 ABSTRACT SummaryBackgroundCentral Europe carries a substantial global burden of ischaemic heart disease (IHD). We aimed to quantify sex-specific differences in IHD case-fatality across 13 Central European countries and to examine the contribution of metabolic, behavioural, and dietary risk factors to these disparities.MethodsWe analysed Global Burden of Disease (GBD) data on IHD from 1990 to 2023 across 13 Central European countries. Population-level case-fatality was assessed using sex-specific age-standardised mortality-to-prevalence ratios (MPRs). Mortality attributable to specific risk factors was normalised to prevalence to derive a case-fatality index (CFI). Z-scores (≥1.96) quantified the significance of sex differences. Associations with gross national income (GNI) per capita were evaluated using Pearson correlation.FindingsIn 2023, there were 6.71 million prevalent IHD cases in the region, of whom 3.01 million (44.8%) were women. From 2011 to 2023, regional MPRs declined from 4.49% to 4.37% in men (2.6% relative decrease) and from 4.59% to 4.42% in women (3.7% relative decrease). However, statistically significant sex disparities persisted in 2023: women had higher MPRs in Croatia (Z = 5.55), Serbia (Z = 2.55), and Czechia (Z = 2.18), whereas men had higher MPRs in Poland (Z = −2.55). Higher GNI per capita was associated with lower MPRs (r = −0.76; p = 0.003). Elevated systolic blood pressure and physical inactivity were prominent (Z > 1.96) contributors to excess female case-fatality, while tobacco use disproportionately (Z > 2.58) affected men, particularly in Poland. Dietary risks contributed to sex disparities: women demonstrated higher CFIs for low intake of fruits, nuts/seeds, vegetables, and seafood omega-3 in several high-disparity countries, while male excess was limited to high sodium and low whole-grain intake in isolated settings.InterpretationDespite overall improvements, significant sex inequalities in IHD case-fatality persist in Central Europe. Differential burdens of metabolic, behavioural, and dietary risks are associated with these disparities, underscoring the importance of sex-specific and country-specific prevention approaches to reduce avoidable cardiovascular mortality.FundingNone.Keywords: Sex factors, Ischaemic heart disease, Mortality, Diet, Risk factors, Central Europe Research in context Evidence before this study We searched PubMed and Embase from database inception to October 2025 using the terms “ischaemic heart disease,” “sex disparities,” “Central Europe,” “mortality,” “prevalence,” and “case-fatality.” Prior studies confirm that Central Europe carries one of the highest global burdens of ischaemic heart disease (IHD), but most analyses focused on incidence or absolute mortality. Evidence on sex differences in IHD outcomes has been inconsistent, is largely drawn from Western Europe or North America, and rarely considers cross-country variation within Central Europe. No previous study has systematically quantified sex-specific case-fatality in Central European countries using standardised estimates of both mortality and prevalence. Added value of this study Using Global Burden of Disease (GBD) 2023 estimates, this study provides the first dedicated cross-country assessment of sex-specific IHD case-fatality across 13 Central European nations. By integrating mortality and prevalence into the mortality-to-prevalence ratio (MPR), and by using risk-attributable case-fatality indices (CFIs), we reveal patterns not detectable from mortality rates alone. Furthermore, by employing Slovenia as a benchmark to overcome data uncertainty, we pinpoint specific dietary deficiencies. We identify persistent female disadvantages in Croatia, Czechia, and Serbia, contrasted by a distinct male disadvantage in Poland. These inequalities correspond to uneven distributions of metabolic, behavioural, and dietary risks, revealing sex- and country-specific profiles of vulnerability, such as elevated systolic blood pressure, physical inactivity, and deficits in protective dietary components among women, and harmful exposures such as tobacco use and high sodium intake among men. Implications of all the available evidence Despite meaningful progress in reducing IHD mortality across Central Europe, inequalities remain pronounced. In several countries, women continue to experience disproportionately higher fatality relative to disease burden, whereas men in Poland show the opposite pattern. These findings highlight the need to complement traditional mortality metrics with sex-specific case-fatality measures in cardiovascular surveillance. Prevention and treatment strategies should be targeted and sex-sensitive, aligned with the dominant risk patterns within each country. Such measures are essential to narrowing persistent cardiovascular inequalities and advancing more equitable health system planning across the region. Introduction Although studies on ischaemic heart disease (IHD) consistently report lower age-standardised prevalence and mortality rates in women than in men,1,2 accumulating evidence shows that women often experience poorer outcomes once a coronary event occurs.3, 4, 5, 6, 7, 8, 9, 10 This paradox raises critical questions about whether excess post-IHD mortality in women reflects biological susceptibility, a differential impact of cardiovascular risk factors, or disparities in access to and receipt of guideline-recommended care. Understanding these mechanisms is challenging because most data on sex-specific IHD outcomes originate from North America and Western Europe. Evidence from other regions remains limited, leaving uncertainty about whether these patterns hold in settings with different health-system structures, socioeconomic histories, and risk-factor profiles. Central Europe is one such underrepresented region. Despite including a mix of high-income and upper-middle–income countries, the region shares features distinct from Western Europe, including post-socialist transitions and health systems shaped by similar organisational models.11 Yet, few studies have examined IHD mortality trends across these countries, and none have systematically assessed sex differences in outcomes. Furthermore, existing multinational analyses of sex disparities, where they exist, often rely on registry data aggregated up to 2014.6 Over the past decade, however, Europe has undergone substantial demographic shifts, including population ageing and increasing life expectancy, that may have altered sex-specific patterns of IHD prevalence, survival, and risk-factor profiles. More recently, our analysis using Global Burden of Disease (GBD) 2021 estimates across 27 European Union (EU) countries identified substantial geographic heterogeneity in sex-specific IHD mortality relative to prevalence and in risk-attributable mortality; however, that analysis included only a subset of the Central European countries considered in the present study.10 In this context, it remains unclear how these sex-specific differences are currently distributed within Central Europe, whether such disparities differ between 2011 and 2023, and whether country-level risk-factor burdens and economic conditions differentially contribute to these patterns. To address these questions, we used GBD 2023 estimates to analyse sex-specific IHD mortality and prevalence across 13 Central European countries from 2011 to 2023. We examined geographic variation, economic gradients, and the contribution of metabolic, behavioural, and dietary risk factors, with the aim of generating regionally comparable evidence to inform strategies aimed at reducing sex-based inequalities in IHD outcomes. Methods Data sources and definitions This study complies with the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER). We used mortality and population estimates for Central European countries from the GBD 2023 study for two benchmark years, 2011 and 2023.1 The present analysis is based entirely on the GBD 2023 release rather than on estimates carried forward from our previous GBD 2021 analysis. Because successive GBD releases incorporate newly available data and methodological updates and re-estimate historical time series, estimates for overlapping calendar years may differ between GBD 2021 and GBD 2023. The Eurostat Health Care Database provided additional information on revascularisation rates.12 These data were further complemented by World Bank economic indicators, specifically the gross national income (GNI) per capita for the preceding calendar year,13 categorised into four income groups: low, lower-middle, upper-middle, and high (Appendix Table 1). IHD mortality estimates in GBD are derived primarily from national civil registration and vital statistics systems reporting International Classification of Diseases-coded causes of death to the WHO Mortality Database and national statistical authorities. All included countries maintain established vital registration systems, although completeness and coding specificity vary. Prevalence and incidence estimates are informed by population surveys, disease registries, and administrative health data where available. Dietary exposure estimates are derived from nationally representative nutrition surveys, household consumption surveys, and food balance sheet data synthesised within the GBD comparative risk assessment framework. Where sex-specific intake data are available, exposures are modelled separately for women and men. In settings where direct survey data are sparse, hierarchical Bayesian models incorporate regional covariates to enhance stability and comparability across countries. Data completeness and quality vary across Central European countries. In settings with high-quality vital registration systems and low fractions of ill-defined causes (e.g., Slovenia, Czechia), cause-of-death attribution relies predominantly on certified International Classification of Diseases-coded mortality data. In countries with incomplete registration or higher proportions of “garbage codes” (e.g., unspecified cardiovascular causes), the GBD framework applies validated redistribution algorithms and Bayesian meta-regression (DisMod-MR 2.1) to probabilistically reassign deaths to specific causes. These procedures improve comparability but introduce model-based uncertainty, which is reflected in the uncertainty intervals (UIs) presented throughout the manuscript. The GBD study classifies sex biologically, based on vital registration systems and population surveys. Accordingly, all analyses were sex-stratified (female/male). For readability and alignment with clinical reporting, we use the terms women and men, recognising that these refer to biological sex rather than gender identity. All data were publicly available, aggregated, and de-identified; therefore, institutional review board approval was not required. Risk factor estimation We selected IHD risk factors based on established causal evidence, including high systolic blood pressure, elevated low-density lipoprotein (LDL) cholesterol, high fasting plasma glucose, tobacco use, and high body mass index (BMI). Definitions followed the GBD 2021 framework.14 Smoking exposure comprised current/former tobacco use plus second-hand smoke, all compared to a theoretical minimum risk level of zero. Theoretical minimum risk exposure levels (TMRELs) for other key risk factors were as follows: blood pressure, 110–115 mmHg; fasting plasma glucose, 4.8–5.4 mmol/L; LDL cholesterol, 0.7–1.3 mmol/L; and BMI, 20–25 kg/m2. Additional modifiable exposures included low physical activity (TMREL: 3000–4500 MET-min/week) and ambient/household air pollution (ozone, PM2.5, and solid fuel use). Health effects of dietary risks We evaluated 12 dietary exposures associated with IHD as defined by the GBD study. GBD dietary risks comprised low consumption of whole grains, fruit, legumes, vegetables, and nuts and seeds; low intake of fibre, seafood omega-3 fatty acids, and polyunsaturated fatty acids; high consumption of red meat, processed meat, and sugar-sweetened beverages; and high sodium intake. Trans-fat data were unavailable for 2023 and were excluded. Low consumption or intake was examined for these foods and nutrients because GBD defines the corresponding risk exposure as intake below the TMREL, representing the intake range associated with the lowest population-level risk. Thus, the classification does not imply that intake above a single “low” threshold is necessarily high or optimal. The TMREL for each dietary component is defined in Appendix Table 2. Handling of unstable risk-factor estimates When GBD uncertainty intervals for risk-factor–attributable mortality included implausible negative values, estimates were considered statistically unstable. In such cases, only point estimates of women-to-men ratios were reported descriptively, flagged as unstable, and excluded from formal Z-score testing. This situation occurred most frequently for certain dietary exposures (e.g., low legume intake or high sugar-sweetened beverage and red-meat intake) and reflects the modelling uncertainty inherent in attributable risk estimation when effect sizes are small or data inputs are limited. Statistical analysis We analysed sex-specific IHD outcomes across Central European countries from 2011 to 2023 using data from the GBD 2023 study. Primary outcomes included age-standardised mortality rates (ASMRs), age-standardised prevalence rates (ASPRs), and mortality-to-prevalence ratios (MPRs), all expressed per 100,000 population and standardised to the GBD standard population structure.15 MPRs, calculated as ASMR divided by ASPR, served as a proxy for population-level case-fatality, enabling cross-country and sex-based comparisons. The mortality-to-prevalence ratio was used as a population-level indicator of mortality relative to prevalent IHD. Intuitively, MPR asks whether mortality is high or low in relation to the number of people living with IHD in a given country and sex group. Because IHD is a chronic condition, prevalence is a more appropriate denominator than incidence: the population at risk of IHD death includes both newly diagnosed individuals and those living with established disease. MPR is therefore conceptually related to mortality-to-incidence ratios used in other GBD-related analyses as indicators of health-system performance, but adapted to the chronic natural history of IHD. For example, a Lancet GBD analysis used the mortality-to-incidence ratio for HIV as a measure of health-system performance.16 MPR should not be interpreted as a directly observed individual-level case-fatality rate or survival estimate. We also assessed GBD-derived ASMRs attributable to specific risk factors, modelled using TMRELs within the GBD and Burden of Proof frameworks. This approach integrates sex-specific exposure estimates, where data permit, relative risks derived from GBD meta-regression models, and population-attributable fractions, yielding estimates of IHD mortality attributable to each risk factor. These are risk-attributable mortality estimates in the GBD comparative risk assessment sense, not simple associations with exposure levels. Mortality attributable to each risk factor was subsequently normalised to IHD prevalence to derive the case-fatality index (CFI). Intuitively, CFI asks whether mortality attributable to a given risk factor is high or low relative to the number of people living with IHD in a given country and sex group. Thus, CFI provides a prevalence-adjusted estimate of risk-attributable fatal burden among individuals living with IHD, rather than a general population exposure measure. CFI should be interpreted as a comparative, population-level index and not as a directly observed individual-level causal estimate. In this context, the term “vulnerability” refers to higher CFI associated with a given exposure, rather than implying intrinsic biological susceptibility. Full methodological details are publicly available (https://github.com/ihmeuw-msca/burden-of-proof). The conceptual rationale for MPR and CFI is further explained in the Appendix. Precision of estimates depends on population size, data density, and the relative contribution of modelled inputs. Prevalence estimates are typically subject to greater uncertainty than mortality estimates due to reliance on survey and registry data. Consequently, derived measures such as MPR and CFI inherit uncertainty from both numerator and denominator. To account for this, we applied the extreme value method to estimate conservative uncertainty bounds. Within the GBD framework, prevalence and incidence estimates are generated using the Bayesian meta-regression model DisMod-MR 2.1, which incorporates cause-specific mortality rates as a key input to ensure internal consistency between epidemiological parameters. In simpler terms, for a highly fatal disease like IHD, mortality data are used to help inform and constrain the prevalence models, particularly where high-quality prevalence data are sparse. As a result, ASMRs and ASPRs are not fully independent quantities. The MPRs therefore do not represent a directly observed case-fatality rate derived from independent numerator and denominator data, but rather a modelled, prevalence-adjusted mortality metric. Its value lies in comparative assessment across countries and sexes rather than in estimating absolute survival probabilities. Following the analytical framework used in our previous European GBD study,10 sex differences were evaluated for both MPR and risk-attributable mortality normalised to IHD prevalence (CFI). Two-sample Z-tests were used for sex comparisons, while women-to-men rate ratios provided complementary descriptive estimates, with values > 1.0 indicating a relatively greater burden in women. Z-scores were used as exploratory hypothesis tests of sex differences in MPR and risk-factor-specific CFI. Conventional thresholds of |Z| ≥1.96 and |Z| ≥2.58 were used to denote evidence compatible with p < 0.05 and p < 0.01, respectively. Standard errors were approximated from the 95% UIs reported by GBD, as detailed in the Appendix. Because multiple comparisons were performed across countries, years, sexes, and risk-factor domains, these tests should be interpreted as exploratory rather than confirmatory. We did not apply formal multiplicity correction; instead, we interpreted findings in relation to effect size, UIs, and consistency across related risk-factor domains. Risk-factor analyses were performed for all countries to describe regional patterns, but particular emphasis was placed on countries where sex differences in MPR were statistically robust or clinically meaningful. We used Pearson's correlation to assess trends (p < 0.05 considered significant), with Shapiro–Wilk tests verifying normality.17 Analyses were conducted in Stata v17.0 using publicly available GBD and World Bank data. Further details on statistical methods and adjustments are provided in the Appendix. Role of the funding source This study had no funding. Results Between 2011 and 2023, ASMRs for IHD declined across Central Europe in both sexes, with relative reductions of 2.6% (95% UI: 0.00%–5.26%) in men and 3.7% (95% UI: 2.81%–5.99%) in women (Table 1). Uncertainty intervals were wider in women, suggesting greater variability in the magnitude of decline. Throughout the study period, men had consistently higher disease burden: by 2023, ASMRs were 1.6-fold higher in men than women, and ASPRs were 1.7-fold higher. Table 1Age-standardised prevalence rate, age-standardised mortality rate, mortality-to-prevalence ratio, and women-to-men ratio in individuals of all ages, per 100,000 inhabitants.CountryAge-standardised prevalence rate of IHD per 100,000 inhabitantsAge-standardised mortality rate of IHD per 100,000 inhabitantsMortality-to-prevalence ratio,%Women-to-men ratio20112023201120232011202320112023MenWomenMenWomenMenWomenMenWomenMenWomenMenWomenAlbania4052.462568.703331.952113.03174.53121.62149.1794.334.314.734.484.461.101.00 Lower bound 95% UI3430.002232.792728.921806.01152.7098.43115.8464.653.213.322.902.58 Upper bound 95% UI4763.252965.193998.472506.09194.52145.79179.72122.355.676.536.596.77Bosnia and Herzegovina4301.082197.943651.872256.12189.55138.23170.77117.184.416.294.685.191.431.11 Lower bound 95% UI3535.152197.942864.161970.42165.70115.23146.5897.603.323.803.363.76 Upper bound 95% UI4997.553032.454361.002594.41216.92158.24195.74140.766.147.206.837.14Bulgaria7223.854822.885242.143099.46252.72152.36210.50121.993.503.164.023.940.900.98 Lower bound 95% UI6471.934386.744787.822684.37239.56138.86194.86109.752.862.663.323.11 Upper bound 95% UI8388.545222.655863.063529.13267.43164.32228.21133.624.133.754.774.98Croatia3754.251917.553473.131475.52200.59137.64147.1791.085.347.184.246.171.341.46 Lower bound 95% UI3503.201717.902747.761274.99189.46124.52137.2280.604.505.942.914.82 Upper bound 95% UI4208.652096.464708.711670.77209.26146.50156.4898.205.978.535.697.70Czechia4455.852214.974035.782035.18235.20147.10168.1796.575.286.644.174.751.261.14 Lower bound 95% UI4024.432002.903221.791813.26222.47131.85157.3585.144.425.333.083.68 Upper bound 95% UI5029.522475.875104.452316.69243.47156.34175.89103.206.057.815.465.69Hungary6548.153764.135451.473120.29259.39160.29216.93129.093.964.263.984.141.071.04 Lower bound 95% UI5563.293365.134736.902765.92247.57144.34204.26116.643.253.503.343.01 Upper bound 95% UI7613.404124.816123.353876.99267.21168.90226.49136.614.805.024.784.94Montenegro4888.592743.603785.122188.98217.34139.61170.69112.854.455.094.515.161.141.14 Lower bound 95% UI4183.932323.303116.161830.19191.08118.07144.3390.603.293.683.233.58 Upper bound 95% UI5815.423204.494469.542531.56244.89162.18203.37137.105.856.986.537.49North Macedonia4194.792708.963154.072023.32199.44144.07155.43112.094.755.324.935.541.121.12 Lower bound 95% UI3765.072351.902661.001751.35177.75123.47135.5794.933.704.013.654.00 Upper bound 95% UI4808.693080.883709.862374.61220.57168.13174.15133.555.867.156.547.63Poland5420.193363.203776.872515.87186.83101.67143.4080.233.453.023.803.190.880.84 Lower bound 95% UI4472.572730.583129.602082.54176.0389.70130.6870.122.672.182.852.35 Upper bound 95% UI6596.464109.024577.722986.17197.48110.42151.8587.334.424.044.854.19Romania3475.252227.043667.572035.98228.95149.05189.96114.526.596.695.185.621.021.09 Lower bound 95% UI2976.182002.833144.531762.08217.36137.06177.93103.554.075.533.744.44 Upper bound 95% UI5337.602480.334762.332330.23239.48157.85202.87123.488.057.886.457.01Serbia3741.481997.003179.471777.16251.33195.20205.80158.626.729.776.478.931.461.38 Lower bound 95% UI3371.111756.902601.251464.29226.37172.04173.34133.865.347.664.566.31 Upper bound 95% UI4239.192247.293801.492120.48277.55217.67241.17188.178.2312.399.2712.85Slovakia4778.482856.453525.121995.37281.16186.63200.28130.755.886.535.686.551.111.15 Lower bound 95% UI4360.612548.843059.491766.39260.75165.73181.54113.845.085.234.364.88 Upper bound 95% UI5130.623166.904162.212332.19300.22203.00217.00143.646.887.967.098.13Slovenia3074.991564.452504.371152.5995.6547.6263.5529.173.113.042.542.530.981.00 Lower bound 95% UI2845.091413.252130.57927.1888.8441.7558.1424.482.552.451.791.82 Upper bound 95% UI3482.881701.103246.221348.07101.5052.1569.6832.543.573.693.273.51Central Europe4841.542938.363892.832315.71217.16134.75170.06102.244.494.594.374.421.021.01 Lower bound 95% UI4385.192665.133467.512094.33208.26123.24160.4692.193.803.843.603.61 Upper bound 95% UI5473.383208.344460.442554.29224.57142.11177.45108.555.125.335.125.18The GBD 2023 definition describes IHD as ICD classes I20–25.9, namely: angina pectoris, acute myocardial infarction, subsequent STEMI and NSTEMI, certain current complications following STEMI and (NSTEMI (within the 28 days), other acute IHD, and chronic IHD.Data and definitions from GBD Database, 2023.Abbreviations: ASMR indicates age-standardised mortality rate; ASPR, age-standardised prevalence rate; GBD, Global Burden of Disease; ICD, International Classification of Diseases; IHD, ischaemic heart disease; MPR, mortality-to-prevalence ratio; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction; UI, uncertainty intervals. Age-standardised prevalence rate, age-standardised mortality rate, mortality-to-prevalence ratio, and women-to-men ratio in individuals of all ages, per 100,000 inhabitants. The GBD 2023 definition describes IHD as ICD classes I20–25.9, namely: angina pectoris, acute myocardial infarction, subsequent STEMI and NSTEMI, certain current complications following STEMI and (NSTEMI (within the 28 days), other acute IHD, and chronic IHD. Data and definitions from GBD Database, 2023. Abbreviations: ASMR indicates age-standardised mortality rate; ASPR, age-standardised prevalence rate; GBD, Global Burden of Disease; ICD, International Classification of Diseases; IHD, ischaemic heart disease; MPR, mortality-to-prevalence ratio; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction; UI, uncertainty intervals. IHD mortality in 2023 ASMRs varied widely across countries (Table 1). Among men, the highest rates occurred in Hungary (216.93) and Bulgaria (210.50), while Serbia (205.80), Slovakia (200.28), and Romania (189.96) recorded the highest rates in women. The lowest ASMRs were observed in Slovenia (men: 63.55; women: 29.17), followed by Poland and Croatia. Higher GNI per capita was associated with lower ASMRs in both sexes; the inverse correlation reached statistical significance in women (r = −0.54, p = 0.04) but not in men (r = −0.36, p = 0.22) (Appendix Fig. 1). IHD prevalence in 2023 Large cross-country differences were also seen in ASPRs (Table 1). Hungary had the highest prevalence for both sexes (men: 5451.47; women: 3120.29), followed by Bulgaria, Montenegro, and Poland; Slovenia consistently had the lowest rates. ASPRs showed no significant association with GNI per capita (women: r = −0.28, p = 0.33; men: r = −0.02, p = 0.95) (Appendix Fig. 2). Relationship between prevalence and mortality In 2023, ASMRs and ASPRs were moderately correlated across countries, reaching statistical significance in men but not in women (women: r = 0.45, p = 0.12; men: r = 0.68, p = 0.019; Appendix Fig. 3A and B). When women and men were analysed together, the correlation strengthened substantially (r = 0.80; p < 0.001), reflecting the strong between-sex gradient in both prevalence and mortality. This divergence supports normalising mortality by prevalence using the MPR to better capture case-fatality across countries. Mortality normalised for prevalence From 2011 to 2023, regional mean MPRs declined from 5.32% to 4.32% in men and from 5.84% to 4.48% in women (Table 1). However, country-level patterns varied substantially (Fig. 1). Analysis of women-to-men MPR ratios in 2023 revealed a predominant female disadvantage across most countries with two notable exceptions: Bulgaria (ratio = 0.98) and Poland (ratio = 0.84). The female disadvantage was most pronounced in Croatia (ratio = 1.46) and Serbia (ratio = 1.38), indicating that the case-fatality for women was 46% and 38% higher than for men, respectively. More modest, yet clear, female disadvantages were observed in Slovakia (1.15), Montenegro (1.14), Czechia (1.14), North Macedonia (1.12), and Bosnia and Herzegovina (1.11). Wide UIs, however, introduce variability in these estimates and warrant further analysis. MPRs for IHD by sex across 13 Central European countries in 2023. Abbreviations: IHD indicates ischaemic heart disease; MPR, mortality-to-prevalence ratio. Z-score analysis of sex disparities in MPR In 2011, women had significantly worse outcomes in 4 of 13 countries—Croatia (Z = 5.64), Serbia (Z = 4.47), Czechia (Z = 4.39), and Bosnia and Herzegovina (Z = 3.16)—whereas men fared worse in Poland (Z = −2.11) and Bulgaria (Z = −1.98) (Fig. 2; Appendix Table 3). Z-score analysis of sex differences in IHD MPRs in Central Europe, 2011–2023. The threshold for statistical significance (∣Z∣ ≥ 1.96 ∣Z∣ ≥ 1.96 corresponds to p < 0.05 ∣Z∣ ≥ 2.58 ∣Z∣ ≥ 2.58 corresponds to p < 0.01. Abbreviations: IHD indicates ischaemic heart disease; MPR, mortality-to-prevalence ratio. By 2023, disparities had narrowed but persisted in Croatia (Z = 5.55), Serbia (Z = 2.55), and Czechia (Z = 2.18). Poland showed a significant reversal, with men experiencing higher mortality burden (Z = −2.55) (Appendix Table 4). Changes in MPRs from 2011 to 2023 MPRs fell significantly in most countries (Appendix Table 5). Both women and men showed significant improvements in Croatia, Czechia, North Macedonia, Romania, Slovakia, and Slovenia. The steepest declines (Z < −2.58) were recorded in Slovenia, Czechia, and Slovakia for both sexes, while Croatia showed particularly large improvements among women. Slovenia, which began with the lowest baseline MPRs, achieved the greatest relative reduction, although a persistent male disadvantage remained. No significant improvement was observed in Albania, Bosnia and Herzegovina, or Montenegro, indicating entrenched inequalities and the need for targeted interventions. MPRs and national income Higher GNI per capita was strongly associated with lower MPRs (r = −0.76; p = 0.003) (Appendix Fig. 4A and B), suggesting better IHD survival in wealthier countries, although country-level heterogeneity remained. This gradient was more pronounced in men (r = −0.50; p = 0.08) than in women (r = −0.37; p = 0.21). Benchmarking Slovenia against six founding EU countries To contextualise Slovenia's IHD case-fatality burden within a Western European framework, we compared its 2023 MPR with that of each of the six founding EU countries (Belgium, France, Germany, Italy, Luxembourg, the Netherlands). Overall, Slovenia's MPR closely aligned with the Western European range. Slovenian women had an MPR of 2.54% (95% UI: 1.79–3.27), and pairwise Z-score tests showed no statistically significant difference with any of the six countries (Z ranged from −0.42 to 1.30, all p > 0.05). This indicates that women in Slovenia experience a case-fatality burden essentially indistinguishable from that of women in the founding EU countries. For men, Slovenia's MPR was 2.53% (95% UI: 1.82–3.51) (Appendix Table 6). When compared individually with the six countries, the only statistically significant difference emerged against France, where Slovenia had a higher MPR (difference +0.98 percentage points; Z = 2.09, p = 0.0365). Comparisons with the other five founding countries, Belgium, Germany, Italy, Luxembourg, and the Netherlands, all yielded non-significant Z-scores (p > 0.05). Thus, apart from a modest excess relative to France, Slovenian men also exhibited case-fatality levels that were statistically comparable to those of most Western European countries. These findings demonstrate that Slovenia's MPR is broadly consistent with Western European benchmarks. Proportion of IHD deaths attributable to risk factors Across all countries, most risk-attributable IHD deaths occurred in men, reflecting higher underlying prevalence. Physical inactivity was an exception, exerting a proportionally greater impact on women (Appendix Tables 7–25). To isolate per-case vulnerability, sex differences were further examined using the CFI, which adjusts risk-attributable mortality for underlying prevalence. CFI for metabolic risk factors In most countries, women exhibited higher CFIs than men for major metabolic risks (high systolic blood pressure, fasting plasma glucose, LDL cholesterol, and BMI), with ratios >1.0 (Fig. 3A; Appendix Tables 7–10). Croatia, Serbia, and Slovakia showed the most pronounced female disadvantage, with women's CFIs >20% higher for all four metabolic risks. Top five countries with the highest CFI for IHD mortality attributable to (A) metabolic and (B) behavioural and environmental risk factors in Central Europe, 2023. The magnitude and uncertainty for all countries are reported in the Appendix. CFI women/CFI men values >1.0 indicate a higher CFI in women. Abbreviations: BMI indicates body-mass index; CFI, case-fatality index; IHD, ischaemic heart disease; LDL-c, low-density lipoprotein cholesterol; MPR, mortality-to-prevalence ratio; SBP, systolic blood pressure. CFI for behavioural and environmental risks Women had substantially higher CFIs for physical inactivity in the Balkans, most notably in Croatia (ratio = 4.57) and Serbia (ratio = 4.11). For air pollution, Croatia (1.47) and Serbia (1.44) showed the clearest female excess. By contrast, tobacco-attributable mortality remained consistently higher in men; in Albania, the male burden was nearly sixfold that of women (ratio = 0.17). These patterns reveal sharply divergent sex-specific vulnerabilities across behavioural and environmental risks (Fig. 3B; Appendix Tables 11–13). CFI for dietary risk factors Between 2011 and 2023, mortality attributable to most dietary risks declined, yet sex disparities persisted. Women in Croatia, Montenegro, and Serbia showed the highest CFIs, particularly for low seafood omega-3 intake (ratios 1.30–1.68) (Fig. 4; Appendix Tables 14–25). Poland showed the strongest male disadvantage, with women-to-men CFI ratios <1.0 across diets high in processed meat and sodium and low in legumes, whole grains, nuts/seeds, seafood omega-3, and vegetables. Top five countries with the highest women-to-men ratio of the CFI for IHD mortality attributable to dietary risk factors in Central Europe, 2023. The magnitude and uncertainty for all countries are reported in the Appendix. CFI women/CFI men values >1.0 indicate a higher CFI in women. Abbreviations: CFI indicates case-fatality index; IHD, ischaemic heart disease. Z-score analysis for metabolic risk factors In 2011, Croatia, Czechia, Bosnia and Herzegovina, and Serbia exhibited significant female disadvantages for high systolic blood pressure (|Z| > 1.96). In 2023, Croatia remained the only country with significant female excess (|Z| > 1.96) (Fig. 5A; Appendix Tables 26–33). Serbia, Czechia and, Bosnia and Herzegovina showed smaller, non-significant female excesses, consistent with residual disparities in MPRs. Z-score analysis of sex differences in IHD mortality in 2023 attributable to (A) metabolic, (B) behavioural, and (C) environmental risk factors in Central Europe. The threshold for statistical significance (∣Z∣ ≥ 1.96 ∣Z∣ ≥ 1.96 corresponds to p < 0.05 ∣Z∣ ≥ 2.58 ∣Z∣ ≥ 2.58 corresponds to p < 0.01. Abbreviation: IHD indicates ischaemic heart disease. Z-score analysis for behavioural risk factors In 2023, tobacco-related IHD mortality was significantly lower in women across all countries (|Z| > 2.58), whereas physical inactivity showed higher burdens in women everywhere, reaching borderline significance in Poland (|Z| ≈ 1.95) (Fig. 5B; Appendix Tables 34–37). Z-score analysis for environmental risk factors No country showed significant sex differences in air-pollution-attributable mortality in 2023 (|Z| < 1.96), indicating similar per-case vulnerability in women and men (Fig. 5C; Appendix Tables 38 and 39). Z-Score analysis for diet-driven mortality: a benchmarking analysis To address wide UIs that obscured within-country significance (Appendix Tables 40–46), we conducted a benchmarking analysis using Slovenia, a country with the lowest low MPRs, as a reference. Estonia, exhibiting the lowest MPRs in 2023 (men 3.14; women 1.77) and statistically indistinguishable from the mean of the 6 founding EU countries (Germany, Italy, France, Belgium, Netherlands, Luxembourg), served as the reference for Z-score benchmarking (Z > 1.96, p < 0.05; Z > 2.58, p < 0.01). This approach revealed significant sex differences (Z > 1.96) for seven dietary risks: low intake of whole grains, fruits, nuts/seeds, vegetables, seafood omega-3 fatty acids and fibre, and high intake of sodium (Fig. 6; Appendix Tables 46–52). The most consistent burdens for both sexes were linked to low intake of whole grains and fibre, with Slovakia exhibiting the broadest and most severe profile. Female-specific disadvantages emerged for selected protective foods: low fruit intake in Croatia and Hungary; low nuts and seeds in Croatia, Czechia, Montenegro, and Serbia; low seafood omega-3 intake in Romania; and low vegetable intake in Croatia and Montenegro. Male-specific excesses were comparatively limited, including high sodium-attributable mortality in Romania and low whole-grain intake in Bulgaria. Together, these findings indicate that sex differences in diet-driven IHD fatality arise from country- and nutrient-specific vulnerabilities, rather than a consistent regional pattern. Benchmark Z-score analysis for sex disparities in IHD mortality attributable to dietary risk factors in Central Europe, 2023. Slovenia is the reference country. The threshold for statistical significance (∣Z∣ ≥ 1.96 ∣Z∣ ≥ 1.96 corresponds to p < 0.05 ∣Z∣ ≥ 2.58 ∣Z∣ ≥ 2.58 corresponds to p < 0.01. Abbreviation: IHD indicates ischaemic heart disease. Access to coronary revascularization Substantial variation in the utilisation of coronary revascularisation procedures was observed across Central Europe in 2023 (Appendix Table 54). To contextualise these rates against disease burden (ASPR), a procedure-to-prevalence ratio (PPR) was calculated. The analysis revealed that a country's PPR does not directly predict its pattern of sex disparity in IHD mortality. For instance, Croatia and Bulgaria had among the highest PPRs in the region (11.0% and 5.2%, respectively). However, their sex-specific MPRs differed markedly: Croatia exhibited a significant disparity disadvantaging women (MPR: 4.1% men vs. 7.8% women), while Bulgaria showed near-identical MPRs between sexes (4.0% men vs. 3.9% women). This pattern indicates that equitable outcomes depend not only on system capacity but also on the fairness of clinical pathways determining who receives treatment. Population coverage and representativeness The GBD 2023 estimates are designed to be nationally representative, providing population-level estimates for each country by integrating multiple data sources, vital registration, health surveys, registries, and epidemiological studies, within a standardised modelling framework across all ages and both sexes. As such, our analyses are generalisable to the entire resident population of each Central European country rather than to selected clinical or registry-based subgroups. To illustrate the population scope of the estimates, in Central Europe in 2023 an estimated 6,713,693 individuals were living with ischaemic heart disease, of whom 3,009,221 (44.8%) were women. The burden of IHD mortality amounted to 150,575 deaths among men and 156,663 deaths among women (Supplemental Tables 55 and 56). Analysing trends from 2011 to 2023, only two countries consistently exhibited a women-to-men mortality ratio below 1.0, indicating a persistently lower mortality risk for women relative to men: Bulgaria and Poland. Notably, Slovenia began the period with a ratio below 1.0 in 2011, but this increased to 1.0 by 2023, indicating a shift towards parity in IHD mortality between sexes. Discussion Our analysis reveals a complex and evolving landscape of IHD across Central Europe, where overall improvements in mortality mask persistent and contrasting sex inequalities. Three interlocking themes emerge: a socioeconomic gradient in survival, enduring sex disparities in fatality once IHD is established, and distinct sex-specific constellations of risk. All analyses are based on country-level, sex-stratified GBD estimates and therefore reflect population-level associations; inferences about individual-level mechanisms or causal pathways are not possible. The GBD regional classification groups countries according to epidemiological similarity, data structure, and health-system context rather than continental geography. Central Europe forms a coherent cluster within this framework, characterised by shared post-transition health systems and persistently elevated cardiovascular mortality compared with Western Europe. Examining sex disparities within this defined regional context allows identification of intra-regional heterogeneity that may be obscured in broader pan-European analyses.18 A clear socioeconomic gradient, while crucial, is an incomplete solution. The strong inverse correlation (r = −0.76; p = 0.003) between national income and case-fatality confirms that wealthier nations generally achieve better IHD survival. However, this association should be interpreted cautiously because national income is also likely to correlate with diagnostic coverage, disease registration, and the completeness of prevalence ascertainment. Thus, lower MPRs in higher-income countries may reflect better survival, but also more complete identification of prevalent IHD. Consequently, despite regional advances, significant sex disparities in case-fatality endure. Women in Croatia, Serbia, and Czechia continue to face substantially higher fatality once IHD is established, (Z = 5.55, 2.55, and 2.18, respectively), whereas men in Poland exhibit the opposite pattern (Z = −2.55). These findings indicate that reductions in absolute mortality do not automatically translate into equitable survival, underscoring the importance of routine, sex-specific monitoring of case-fatality. To understand the drivers of these disparities, we examined the lethality of specific risk factors among individuals living with IHD. At the population level, the overall disparity in any country appears to be the net result of a balance between opposing forces a male disadvantage domain, dominated by tobacco use, consistent with global burden estimates,19 and a female disadvantage domain, driven by physical inactivity, potentially linked to frailty or sarcopenia as well as to social and behavioural contexts that may limit opportunities for regular physical activity,20 elevated metabolic vulnerability, and deficits in protective foods, as described in previous population-based dietary surveys.21 In countries like Croatia and Serbia, the female disadvantage domain predominates, with women bearing a substantially higher per-case mortality burden from physical inactivity (Z = 3.66 and 3.18, respectively) and elevated systolic blood pressure, significantly higher in Croatia (Z = 2.23) and directionally similar in Serbia (Z = 1.87). These findings align with prior evidence indicating that hypertension contributes more strongly to ischaemic complications in women than in men.22,23 In contrast, Poland presents a unique case where the absence of a strong female disadvantage in these areas leaves the universal male hazard from tobacco unopposed, helping to explain the reversal of the sex gap in that country. Diet formed one component of a broader triad of population-level indicators, alongside metabolic risk and physical inactivity, associated with excess female case-fatality across the region. These observations are consistent with established cardioprotective dietary patterns, including Mediterranean and plant-forward models, which emphasise fruits, vegetables, whole grains, nuts, seeds, and marine-derived omega-3 fatty acids. Such dietary frameworks are widely recognised as foundational to cardiovascular prevention across Europe. The country-specific female deficits identified in our analysis therefore reflect departures from dietary patterns already supported by strong outcome evidence.24, 25, 26 Because dietary estimates may carry wider UIs, we used Slovenia, the country with the lowest case-fatality, as an empirical benchmark. A prominent finding was that low intake of nuts and seeds was the only dietary factor consistently associated with a significant female disadvantage in all three high-disparity countries, Croatia, Serbia, and Czechia, suggesting a shared and potentially tractable population-level pattern. In addition, country-specific dietary deficits further amplified female risk, most notably low fruit and vegetable intake in Croatia. These suboptimal dietary patterns are biologically plausible contributors to higher fatal burden, because low intake of fruit, vegetables, nuts, seeds, and omega-3-rich foods has been linked to higher blood pressure load, impaired vascular function, inflammation, and adverse cardiometabolic profiles.27,28 Structured dietary counselling following an IHD diagnosis remains critically underprovided across Europe, with reports suggesting only 10–30% of eligible patients have access to such programs.29,30 This implementation gap represents a missed opportunity to address a key population-level indicator of sex disparities in post-IHD outcomes. Closing this gap requires counselling that recognises a central paradox: although women often play a central role in food purchasing and preparation within households, they may not consume optimal diets themselves. Therefore, effective interventions must be designed to address the individual-level barriers, such as intra-household allocation, time constraints, and competing priorities, that have been hypothesised to lead to these consumption gaps. Our ecological data cannot directly test these hypothesised mechanisms, but they provide a signal that such factors warrant investigation in individual-level studies. This female pattern stands in sharp contrast to the male experience. Male-specific dietary excesses were confined to isolated exposures, such as high sodium intake in Romania or low whole-grain intake in Bulgaria, and did not correspond to broader sex disparities in IHD mortality. This asymmetry suggests that diet-related female disadvantages are not only more frequent but also more closely tied to excess death at the population level. These findings generate testable hypotheses for future research and implementation studies. While dietary improvement benefits all adults,31 the observed sex- and country-specific patterns identify settings where further evaluation is needed to determine whether existing universal prevention strategies reach women and men equitably, and whether additional targeted approaches may improve outcomes. Taken together, these risk patterns prompted further examination of why the CFI associated with dietary and metabolic exposures is higher in women in certain countries. Differences in physiological responses have been hypothesised in the literature, including the menopausal transition, characterised by declining oestrogen levels, is associated with adverse lipid changes and vascular dysfunction, potentially amplifying the impact of inadequate intake of omega-3–rich foods and micronutrient-dense sources such as nuts and seeds.32, 33, 34, 35 These mechanisms provide plausible pathways through which protective food deficits may disproportionately affect women with established IHD. In addition, pharmacologic exposures may further shape cardiometabolic trajectories in midlife and older women. Longitudinal data indicate that the use of weight-promoting medications, including certain antidepressants, beta-blockers, and insulin, is associated with greater increases in BMI and waist circumference over time, with a dose–response relationship according to the number of such agents prescribed.36 Although medication use was not assessed in this ecological analysis, treatment-related weight gain may compound hypertension and dysglycaemia, thereby amplifying metabolic patterns among women with established IHD. However, physiological hypotheses alone do not fully account for the geographical concentration of female dietary disadvantage we observed. Socio-economic conditions in parts of Central Europe frequently intersect with women's nutritional needs in ways that may deepen population-level dietary gaps. Higher rates of food insecurity among women, unequal household food allocation, and gendered norms influencing food selection may restrict consistent access to nutrient-dense foods.37 These challenges may be often compounded by “time poverty” resulting from unequal domestic and caregiving responsibilities, which may limit opportunities to prepare meals based on fresh produce and cardioprotective foods.38 The combination of higher physiological requirements and constrained access to protective nutrients is compatible with the hypothesis of a structural paradox, whereby women with IHD appear to experience relative deprivation of protective foods despite potentially greater nutritional needs. This intersectional disadvantage was especially visible in Croatia and Serbia, the two countries with the largest sex gaps in case-fatality. Although Croatia is a high-income country, it maintains one of the highest at-risk-of-poverty rates in the EU (21.7%), while Serbia, an upper-middle–income country, demonstrates similarly high levels of social vulnerability (24.3%).39 These socioeconomic pressures may disproportionately be associated with women's access to protective foods, which may help to explain the pronounced sex gaps in Croatia and Serbia.40,41 Czechia, however, offers a contrasting pattern, one where excess female risk emerges even in the absence of broad socioeconomic disadvantage. Unlike Croatia and Serbia, Czechia is a high-income country with low levels of poverty (approximately 9.5%), yet it still exhibits a significant female disadvantage in IHD case-fatality. Our benchmark analysis showed that men and women alike have broad deficits in whole grains, fibre, and nuts/seeds, suggesting a general departure from cardioprotective dietary patterns. Within this population-wide deficit, women consistently showed a deeper shortfall in nuts and seeds, foods exceptionally rich in polyunsaturated fatty acids, vitamin E, essential minerals, and other bioactive compounds and integral components of Dietary Approaches to Stop Hypertension (DASH), Mediterranean, and Nordic dietary patterns.42,43 In a context where both sexes share multiple lifestyle risk factors, even a comparatively modest additional deficit among women could plausibly be sufficient to produce measurable sex differences in case-fatality. Beyond intakes of individual foods, overall diet quality and dietary diversity offer complementary perspectives. An umbrella review found that higher adherence to diet quality indices such as the Alternate Healthy Eating Index (AHEI), DASH, and Healthy Eating Index (HEI) reduces CVD mortality.44 However, the specific role of dietary diversity, the variety of foods consumed across and within food groups, remains less certain. A 2026 systematic review concluded that current evidence is insufficient to determine whether including diversity in diet quality measures improves prediction of health outcomes.45 In parallel, a broader perspective linking diet, biodiversity, and health is emerging. A 2025 scoping review reported positive associations between food biodiversity, nutritional adequacy, and reduced mortality.46 These findings raise the possibility that post-transition changes in Central European agricultural systems and food supply chains have reduced dietary species richness, contributing to observed deficits in protective foods, particularly among women. However, this hypothesis remains speculative and requires formal testing. The use of Z-score testing helped distinguish the most statistically robust sex disparities from broader patterns of unequal outcomes. Applying this stringent criterion to the 2023 MPRs confirmed significant female disadvantage only in Croatia, Serbia, and Czechia, the three countries where excess case-fatality was both large and statistically undeniable. However, when using a predefined threshold of an MPR more than 10% higher in women, a measure of effect size rather than statistical certainty, a wider set of countries (Bosnia and Herzegovina, Montenegro, North Macedonia, and Slovakia) also exhibited substantial female disadvantage. These complementary metrics offer a fuller interpretation: Z-scores identify the most irrefutable disparities, while effect-size thresholds highlight countries where inequality is widespread and potentially actionable despite wider UIs. For health-system planning, this dual perspective is essential, ensuring that interventions are guided not only by statistical certainty but also by the magnitude and public-health relevance of sex-specific gaps in survival. Beyond risk factors, system-level capacities and biases further shape these inequalities. While revascularisation procedures are linked to improved outcomes,47 our findings suggest that neither high nor low procedural capacity guarantees equity. Countries with high procedural capacity, like Croatia, still exhibited marked female disadvantage, indicating problems with equitable allocation. Conversely, in low-capacity settings like Poland, overall scarcity appears to create a zero-sum environment that can disadvantage men. These contrasting patterns suggest that the equity of allocation, not simply the volume of procedures, plays a critical role in influencing sex differences in IHD outcomes across Central Europe. Our ecological findings on sex-specific MPR align with, and are complemented by, available individual-level data. In Poland, the marked male disadvantage in prevalence-adjusted IHD mortality corresponds with findings from the PL-ACS registry, which reported a higher proportion of sudden out-of-hospital cardiac arrests in men.48 Conversely, in Serbia, the elevated female disadvantage in mortality relative to prevalence is consistent with data from Belgrade-area coronary care units, where women with ST-elevation myocardial infarction had significantly higher in-hospital mortality, even after adjusting for age and comorbidities.49 Our study has limitations. First, it relies on modelled GBD estimates rather than primary clinical datasets, and the precision of results depends on the completeness and quality of vital registration systems within each country. Although GBD applies standardised redistribution of ill-defined causes and hierarchical Bayesian meta-regression to enhance comparability, variation in vital registration completeness, garbage-code fractions, and population size across countries may influence the precision of mortality and prevalence estimates. Prevalence modelling, in particular, may be more sensitive to sparse input data, potentially wideningUIs in smaller countries or sex-specific strata. Because prevalence estimates may differ in precision between countries and between sexes, apparent differences in MPR could theoretically reflect denominator instability rather than true outcome variation. To reduce this risk, we based interpretation primarily on statistically significant differences and examined UIs in relation to the magnitude of observed effects, avoiding emphasis on directional patterns where precision was limited. Consequently, while our use of GBD data maximises comparability, apparent differences between countries, especially those with smaller populations, should be interpreted cautiously and considered hypothesis-generating where confidence intervals are wide. Second, the analysis compared two benchmark years, 2011 and 2023, and therefore was not designed to characterise short-term annual variation. This approach was chosen because GBD annual estimates incorporate model-based interpolation and smoothing where empirical observations are incomplete, and year-to-year fluctuations may therefore not represent independent epidemiological changes. Nevertheless, genuine intermediate changes between the two benchmark years cannot be excluded. Third, because prevalence estimates in GBD are partly constrained by cause-specific mortality inputs within DisMod-MR, the numerator (mortality) and denominator (prevalence) of the MPR are structurally interrelated. This modelling dependence may attenuate extreme variability and limit interpretation of MPR as an independent measure of survival. Accordingly, MPR should be interpreted as a comparative indicator of relative mortality burden rather than as a direct estimate of case-fatality or ‘fatal disease impact” rather than as a direct estimate of case-fatality. Significant differences in MPR between countries or sexes are therefore more likely to reflect true underlying differences in disease outcomes, rather than being purely an artifact of this modelling interdependence. Fourth, the ecological design precludes causal inference at the individual level and cannot account for treatment differences, comorbidities, or delays in care that may underlie sex disparities. In particular, the analysis does not directly capture differences in treatment after IHD diagnosis. EUROASPIRE surveys have shown substantial cross-country variation in guideline-recommended risk factor control among patients with established IHD.50 Because GBD-derived exposure estimates reflect population-level risk rather than post-event treatment adherence, we cannot disentangle the relative contributions of baseline risk-factor burden and differences in treatment intensity to observed case-fatality patterns. Furthermore, dietary exposure estimates in GBD are derived from heterogeneous sources, including nationally representative nutrition surveys, household consumption surveys, and food balance sheet data. In settings where direct survey data are sparse, estimates rely more heavily on hierarchical Bayesian modelling, which introduces additional uncertainty. This is reflected in the wide UIs for several dietary risks and limits the precision of country- and sex-specific comparisons. To address this uncertainty, we used Slovenia as a benchmark because it had the lowest MPR in the region. We confirmed that Slovenia's MPR is statistically comparable with that of the six founding countries of the EU, supporting its use as a reference for identifying relative sex disparities. Fifth, although the MPR and the CFI provide complementary population-level proxies of fatality among individuals with IHD, these measures cannot fully capture heterogeneity in clinical presentation, intensity of care, or treatment pathways within countries. Sixth, the GBD framework does not distinguish among ischaemic heart disease subtypes, preventing assessment of whether sex disparities differ by clinical phenotype; this is relevant given evidence that sex differences in outcomes vary across presentations such as ST-elevation myocardial infarction.4 Seventh, some dietary risks showed implausible negative uncertainty bounds and were therefore excluded from formal Z-score testing, limiting our ability to draw firm conclusions about their sex-specific effects. This limitation is particularly relevant for dietary exposures, for which country- and sex-specific estimates may rely more heavily on modelled data where direct intake surveys are sparse. The Z-score analyses involved multiple comparisons across countries, years, sexes, and risk-factor domains. No formal multiplicity correction was applied; therefore, isolated statistically significant findings should be interpreted cautiously. We emphasised findings that were consistent across related metrics or risk-factor domains and that showed both statistical evidence and meaningful effect size. Finally, the analysis does not incorporate broader determinants, such as socioeconomic position, education, or ethnicity, that may interact with sex to shape IHD outcomes. Despite these limitations, the study provides regionally comparable modelled evidence that sex-specific inequalities in IHD case-fatality remain significant in Central Europe, calling for tailored, sex-sensitive strategies in prevention, treatment, and health-system planning. In conclusion, the burden of IHD in Central Europe is not a monolithic challenge but a mosaic of distinct, sex-specific risk landscapes. The path to equity lies not in uniform interventions, but in tailored strategies that address the unique population-level profiles of men and women within each national context (Panel 1). This requires a dual-track approach: confronting the pervasive male tobacco epidemic while addressing the female triad of inactivity, poor diet, and metabolic risk. Slovenia demonstrates that low case-fatality is achievable; the task for the region is to translate this benchmark into targeted action that corrects the preventable risks driving excess fatality in each sex. Policy implications ∗Despite declining mortality, sex disparities in IHD outcomes persist in Central Europe. Women in Croatia, Czechia, and Serbia and men in Poland experience excess mortality relative to disease prevalence and should be considered priority populations for targeted cardiovascular action. Implementation will require tailored approaches that respect varying health-system capacities and economic resources across the region. Despite declining mortality, sex disparities in IHD outcomes persist in Central Europe. Women in Croatia, Czechia, and Serbia and men in Poland experience excess mortality relative to disease prevalence and should be considered priority populations for targeted cardiovascular action. Implementation will require tailored approaches that respect varying health-system capacities and economic resources across the region. ∗In women, excess case-fatality is closely aligned with metabolic risk (elevated systolic blood pressure), physical inactivity, and inadequate intake of cardioprotective foods. Health systems should strengthen hypertension detection and control in women, expand structured cardiac rehabilitation and physical training after IHD, and national nutrition policies should prioritise increased consumption of fibre-rich foods, vegetables, nuts, and seeds. However, these interventions face challenges including limited access to preventive services in rural areas, cultural barriers to physical activity, and higher costs of protective foods in lower-income settings. In women, excess case-fatality is closely aligned with metabolic risk (elevated systolic blood pressure), physical inactivity, and inadequate intake of cardioprotective foods. Health systems should strengthen hypertension detection and control in women, expand structured cardiac rehabilitation and physical training after IHD, and national nutrition policies should prioritise increased consumption of fibre-rich foods, vegetables, nuts, and seeds. However, these interventions face challenges including limited access to preventive services in rural areas, cultural barriers to physical activity, and higher costs of protective foods in lower-income settings. ∗In Poland, men experience disproportionate mortality relative to prevalence; intensified tobacco-control and male-focused cessation programs are warranted. Feasibility may be constrained by tobacco industry influence, low health literacy in some subgroups, and limited funding for cessation services, but Poland's strong track record in tobacco legislation provides a foundation for further action. In Poland, men experience disproportionate mortality relative to prevalence; intensified tobacco-control and male-focused cessation programs are warranted. Feasibility may be constrained by tobacco industry influence, low health literacy in some subgroups, and limited funding for cessation services, but Poland's strong track record in tobacco legislation provides a foundation for further action. ∗Cardiovascular surveillance systems should complement traditional mortality statistics with sex-specific, prevalence-adjusted indicators such as the MPR to better detect outcome inequalities. Adopting these metrics requires investment in data infrastructure, training, and cross-national harmonisation, which may be difficult in countries with competing health priorities. Cardiovascular surveillance systems should complement traditional mortality statistics with sex-specific, prevalence-adjusted indicators such as the MPR to better detect outcome inequalities. Adopting these metrics requires investment in data infrastructure, training, and cross-national harmonisation, which may be difficult in countries with competing health priorities. ∗Coordinated regional strategies addressing metabolic control, behavioural risk reduction, and equitable care delivery are essential to reduce preventable cardiovascular deaths and achieve WHO non-communicable disease targets. Achieving this coordination will depend on political will, sustained funding, and mechanisms for sharing best practices across countries with different socioeconomic realities. Coordinated regional strategies addressing metabolic control, behavioural risk reduction, and equitable care delivery are essential to reduce preventable cardiovascular deaths and achieve WHO non-communicable disease targets. Achieving this coordination will depend on political will, sustained funding, and mechanisms for sharing best practices across countries with different socioeconomic realities. Contributors RB conceived and designed the study, conducted formal analysis, investigation, methodology, supervision, validation, visualisation, writing the original draft, and review and editing. TR conducted formal analysis, investigation, visualisation, writing—original draft, and writing—review and editing. EC contributed to formal analysis, investigation, methodology, visualisation, writing the original draft, and review and editing. BM contributed to formal analysis, validation, and review and editing. LB, SAS, OM, DM, NT, VV, MG and CPG contributed to writing—review and editing. RB, TR, and EC directly accessed and verified the underlying data. RB had final responsibility for the decision to submit the manuscript for publication. Data sharing statement To download the data used in these analyses, please visit the Global Health Data Exchange GBD 2023 website at https://ghdx.healthdata.org/gbd-2023. Editor note The Lancet Group takes a neutral position with respect to territorial claims in published maps, text, tables, and institutional affiliations. Declaration of interests Bela Merkely has received institutional grants (for the Heart and Vascular Center of Semmelweis University): Biotronik, Boehringer-Ingelheim, DUKE Clinical Institut, Eli Lilly, Novartis; consulting fees from Boehringer-Ingelheim, Daiichi Sankyo, DUKE Clinical Institut, Novartis. Sonia Anand has received grants from Population Health Research Institute, Canadian Institutes of Health Research Foundation grants (FDN-143255), Public Health Agency of Canada, Heart & Stroke; consulting fees from Bayer, Janssen Pharmaceuticals, Eli Lilly, Novartis Pharmaceuticals Canada, Novo Nordisk, Daiichi Sankyo, Regeneron; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Bayer, Janssen Pharmaceuticals, Eli Lilly, Novartis Pharmaceuticals Canada, Novo Nordisk, Daiichi Sankyo, Regeneron; Dr Anand also participated in Heart & Stroke National Advisory Board; Dr Sonia Anand is an Associate Vice-President of Global Health; McMaster University, Department of Medicine's Associate Chair of Equity and Diversity; McMaster University and is on Editorial Boards of BMJ and Circulation. Other financial or non-financial interests are Tier 1 Canada Research Chair in Ethnicity and CVD (#CRC-2017-00024) and Heart & Stroke Foundation Chair in Population Health. Chris Gale received grants from British Heart Foundation, National Institute for Health Research, ESC; consulting fees from AstraZeneca, Boston Scientific, Menarini, Novartis, Boehrningher-Ingleheim, MSD; Support for attending meetings and/or travel from AstraZeneca; Dr Gale also participated on the data safety monitoring boards of BHF TARGET CTCA trial; Dr Gale has stocks in CardioMatics. Martha Gulati payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Medtronic, Edwards, Bayer; participated on a data safety monitoring board for Merck, and is Immediate Past President of the American Society for Preventive Cardiology. The other authors have nothing to disclose. Acknowledgements This research was conducted as part of the broader work of The Lancet Regional Health—Europe Commission on Inequities and Disparities in Cardiovascular Health. This study received no funding Footnotes Supplementary data related to this article can be found at https://doi.org/10.1016/j.lanepe.2026.101846. Supplementary data Appendix Figures and Tables References Associated Data Supplementary Materials Appendix Figures and Tables